Rich Pharmaceuticals, Inc (Rich)

Oncology Corporate Profile

HQ Location

9595 Wilshire Boulevard, Ste. 900
Beverly Hills, CA 90045

Company Description

Rich Pharmaceuticals is a biopharmaceutical company that is focused on the development of its lead product, RP-323 (12-O-tetradecanoylphorbol-13-acetate), for the treatment of acute myelogenous leukemia (AML) in refractory patients.

Website: http://www.richpharmaceuticals.com/

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
RP-323tetradecanoylphorbol acetateAcute Myelogenous Leukemia (AML)II
RP-323tetradecanoylphorbol acetateMyelodysplastic Syndrome (MDS)II

View additional information on product candidates here »

Source: http://www.richpharmaceuticals.com/

Recent News Headlines

How to Understand The Rise In The Number Of Cancer Cases by Richard Schilsky, MD

11/1/2016 11:23 am

(Philadelphia Inquirer/Diagnosis: Cancer blog) Oct 31, 2016 - The Centers for Disease Control and Prevention (CDC) reports that, between 2010 and 2020, the number of new cancer cases in the United States will increase by about 24% in men (more than 1 million cases per year), and by about 21% in women (more than 900,000 cases per year).

Study Yields Rich Dossier of Cancer-Linked Protein's Associates

10/28/2016 12:10 pm

(Brown University) Oct 24, 2016 - By developing an atomic-scale picture of how the cancer-linked enzyme PP2A binds to other proteins, Brown University researchers have developed a new list of nearly 100 of its potential partners.

Born Rich or Poor? Where You Begin Life Affects Cancer Risk Later

10/17/2016 11:15 am

(HCI) Oct 13, 2016 - Researchers at Huntsman Cancer Institute (HCI) at the University of Utah announced today the results of a study that found that circumstances in childhood, such as parental occupation at birth and neighborhood income, may be associated with different risks of certain cancers later in life.

Levi Garraway, M.D., Ph.D., to become Senior Vice President of Global Oncology at Lilly, Succeeding Richard Gaynor, M.D., Who is Retiring after a Distinguished Career

9/14/2016 12:01 pm

(Lilly) Sept 14, 2016 - Eli Lilly and Company today announced that Levi Garraway, M.D., Ph.D., a world leader in the analysis of cancer genomics and resistance to targeted therapies, will join Lilly as senior vice president, Global Development & Medical Affairs, for Lilly's Oncology business on January 1, 2017.

ASCO Applauds Selection of Richard Pazdur, MD, to Lead New FDA Oncology Center of Excellence

6/29/2016 12:41 pm

(ASCO) June 29, 2016 - "ASCO commends Food and Drug Administration (FDA) Commissioner Dr. Robert Califf for his selection of Dr. Richard Pazdur to lead the agency’s new Oncology Center of Excellence."

The World's Richest Doctor Wants to Revolutionize Cancer Treatment By Making It Tailor-Made

6/3/2016 01:37 pm

(Business Insider) June 3, 2016 - Dr. Patrick Soon-Shiong, the oncologist who has been dubbed the world's richest doctor, has spent the last decade quietly plotting a big change in the way cancer is treated.

Penn Cancer Center Founder Richard "Buz" Cooper Dies

2/3/2016 11:57 am

(The Daily Pennsylvanian) Feb 3, 2016 - Recently, the Penn community lost one of its finest members — a doctor, researcher, leader and teacher.

BMS and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute Enter Into a Collaboration Agreement as Part of U.S. Immuno-Oncology Rare Population Malignancy Program

12/18/2015 11:48 am

(Bristol-Myers) Dec 17, 2015 - Bristol-Myers Squibb Company and The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) today announced that they have entered into a collaborative agreement as part of Bristol-Myers Squibb’s Immuno-Oncology Rare Population Malignancy (I-O RPM) program in the U.S.

NCCS Celebrates “Focus on the Care” Reception in Honor of Dr. Richard Pazdur and Ellen Goodman

10/26/2015 11:38 am

(NCCS) Oct 22, 2015 - Last night survivors, advocates, researchers, innovators, and friends gathered at our 2015 Focus on the Care reception in celebration of two honorees who have used their unique talents to help the millions of people affected by cancer.

Transgenomic Launches Ultra-High Sensitive ICEme™ Mutation Enrichment Kits Enabling Turbocharged Cancer Research on Existing Platforms

7/1/2015 12:23 pm

(Transgenomic) July 1, 2015 - Transgenomic, Inc., a global biotechnology company advancing precision medicine through advanced diagnostic tests and clinical and research services, today announced that its ICEme™ Mutation Enrichment Kits for cancer research are now commercially available to researchers worldwide.

Congratulations to FDA’s Dr. Richard Pazdur, Recipient of the AACR’s Prestigious Distinguished Public Service Award

4/23/2015 12:58 pm

(FDA.gov/FDA Voice blog) Apr 21, 2015 - The American Association for Cancer Research (AACR) has awarded its 2015 Distinguished Public Service Award to Dr. Pazdur.

AACR, ABC News’ Dr. Richard Besser Use Twitter’s Periscope to Live Stream “Breakthroughs in Cancer Research” From 2015 Annual Meeting

4/22/2015 11:38 am

(AACR) Apr 22, 2015 - The American Association for Cancer Research (AACR) and Richard Besser, MD, ABC News' chief health and medical editor, joined forces Tuesday afternoon on Besser's Twitter chat to share stories, observations, and significant research from the nation's top cancer researchers in conjunction with the AACR Annual Meeting, held April 18 to 22, in Philadelphia.

Richard M. Goldberg MD Awarded Society for Translational Oncology's Pinedo Prize

4/10/2015 12:28 pm

(The Business Journals) Apr 10, 2015 - The Society for Translational Oncology (STO) is pleased to announce that Richard M. Goldberg, MD, internationally renowned gastrointestinal oncologist and physician-in-chief at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), has been named recipient of the 2015 Bob Pinedo Cancer Care Prize.

Juno, Novartis End CAR-T Patent Fight, With Juno A Little Richer

4/7/2015 12:47 pm

(Xconomy Seattle) Apr 6, 2015 - Juno Therapeutics and Novartis are cancer immunotherapy rivals, but Juno now has a rooting interest in Novartis’s success.

The World's 50 Greatest Leaders: #42 Richard Pazdur

3/30/2015 12:24 pm

(Fortune) Mar 29, 2015 - Rarely does one hear anybody celebrate the FDA. But lately the agency’s gatekeeper for cancer drugs is getting nearly universal praise for his effort to speed promising medications to market.

Lung Cancer Now Top Killer for Women in Rich Nations

2/4/2015 11:26 am

(ABC News/Associated Press) Feb 4, 2015 - For the first time, lung cancer has passed breast cancer as the leading cause of cancer deaths for women in rich countries.

340B: Serving Vulnerable Patients or Enriching Hospitals?

12/3/2014 12:13 pm

(Medscape Medical News) Dec 2, 2014 - David Peace, MD, has worked at the University of Illinois at Chicago in the Division of Hematology/Oncology for close to two decades, treating a socioeconomic and ethnically diverse population of cancer patients, two thirds of whom lack adequate health insurance.

The Burden Of Colon Cancer Shifts From Rich To Poor

11/11/2014 11:58 am

(NPR/Shots blog) Nov 11, 2014 - According to a paper published Monday in the Journal of Clinical Oncology, in the past few decades trends have shifted in those most at-risk to die from colorectal cancer.

Merck of Germany to Acquire Sigma-Aldrich for $17 Billion

9/22/2014 12:48 pm

(New York Times/DealBook) Sept 22, 2014 - Merck of Germany said on Monday that it had agreed to acquire the life sciences company Sigma-Aldrich for $17 billion.

Fighting Prostate Cancer with a Tomato-rich Diet

8/27/2014 11:55 am

(University of Bristol [UK]) Aug 27, 2014 - Men who eat over 10 portions a week of tomatoes have an 18 percent lower risk of developing prostate cancer, new research suggests.